Supernus Pharmaceuticals (SUPN) Total Non-Current Liabilities (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Total Non-Current Liabilities data on file, last reported at $404.4 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $404.4 million, up 30.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $404.4 million (up 30.82% YoY), and the FY2025 annual result was $359.7 million, up 10.76% from the prior year.
• Total Non-Current Liabilities rose to $404.4 million in Q1 2026 per SUPN's latest filing, from $359.7 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $841.6 million in Q2 2022 and troughed at $288.6 million in Q3 2024.
• A 5-year average of $484.6 million and a median of $364.4 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities plunged 62.09% in 2023, then surged 30.82% in 2026.
• A 5-year view of Total Non-Current Liabilities shows it stood at $807.6 million in 2022, then tumbled by 56.07% to $354.8 million in 2023, then declined by 8.47% to $324.7 million in 2024, then climbed by 10.76% to $359.7 million in 2025, then grew by 12.44% to $404.4 million in 2026.
• Business Quant data shows SUPN's Total Non-Current Liabilities at $404.4 million in Q1 2026, $359.7 million in Q4 2025, and $369.9 million in Q3 2025.